Susan Tinsley Schumer, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quinazolines | 5 | 2009 | 1356 | 0.440 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2021 | 450 | 0.280 |
Why?
|
| Alopecia | 1 | 2007 | 382 | 0.230 |
Why?
|
| Granulosa Cell Tumor | 1 | 2003 | 71 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2008 | 5221 | 0.200 |
Why?
|
| Ovarian Neoplasms | 3 | 2021 | 4838 | 0.180 |
Why?
|
| Lung Neoplasms | 5 | 2008 | 13102 | 0.180 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2005 | 740 | 0.180 |
Why?
|
| Pyrimidinones | 1 | 2021 | 371 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 2016 | 0.140 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 426 | 0.140 |
Why?
|
| Radiopharmaceuticals | 1 | 2005 | 2645 | 0.130 |
Why?
|
| Glycoproteins | 1 | 2003 | 2263 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2020 | 1275 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 2455 | 0.100 |
Why?
|
| Uterine Neoplasms | 1 | 2021 | 1513 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2021 | 1972 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 5172 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 11524 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1353 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 6234 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 3462 | 0.090 |
Why?
|
| Metalloproteases | 1 | 2008 | 62 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2007 | 13695 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 9239 | 0.070 |
Why?
|
| Survival Rate | 3 | 2020 | 12788 | 0.060 |
Why?
|
| Exercise | 1 | 2021 | 5615 | 0.060 |
Why?
|
| Telemedicine | 1 | 2021 | 2872 | 0.060 |
Why?
|
| Carboplatin | 1 | 2006 | 801 | 0.060 |
Why?
|
| Climacteric | 1 | 2003 | 57 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2008 | 5535 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2005 | 648 | 0.050 |
Why?
|
| Testicular Hormones | 1 | 2003 | 188 | 0.050 |
Why?
|
| Inhibins | 1 | 2003 | 211 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 9274 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2006 | 1708 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 1157 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2003 | 385 | 0.050 |
Why?
|
| Deoxycytidine | 2 | 2020 | 826 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2003 | 408 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2005 | 726 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2003 | 402 | 0.050 |
Why?
|
| Neutropenia | 1 | 2005 | 895 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2006 | 1486 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 4933 | 0.040 |
Why?
|
| Isoxazoles | 1 | 2020 | 216 | 0.040 |
Why?
|
| Platinum | 1 | 2020 | 233 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 10943 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2005 | 3479 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 1770 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2009 | 2063 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 781 | 0.040 |
Why?
|
| Anemia | 1 | 2005 | 1506 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2009 | 20822 | 0.030 |
Why?
|
| Aged | 7 | 2021 | 163280 | 0.030 |
Why?
|
| Estradiol | 1 | 2003 | 2020 | 0.030 |
Why?
|
| Middle Aged | 9 | 2021 | 213383 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2007 | 4554 | 0.030 |
Why?
|
| Female | 11 | 2021 | 380194 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 39050 | 0.030 |
Why?
|
| Pyrazines | 1 | 2020 | 1230 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2008 | 7880 | 0.030 |
Why?
|
| Mutation | 2 | 2008 | 29786 | 0.030 |
Why?
|
| Disease Progression | 2 | 2008 | 13284 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2006 | 11031 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2003 | 2616 | 0.030 |
Why?
|
| Humans | 14 | 2021 | 744343 | 0.030 |
Why?
|
| Apoptosis | 1 | 2007 | 9727 | 0.020 |
Why?
|
| Motivation | 1 | 2021 | 1971 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2021 | 5078 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2008 | 23338 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2021 | 8324 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 892 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2008 | 243 | 0.020 |
Why?
|
| Age Factors | 1 | 2003 | 18370 | 0.020 |
Why?
|
| Filgrastim | 1 | 2005 | 133 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 57776 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2008 | 638 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2006 | 363 | 0.020 |
Why?
|
| Incidence | 1 | 2003 | 20947 | 0.020 |
Why?
|
| Time Factors | 1 | 2006 | 40075 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 9959 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2009 | 1619 | 0.010 |
Why?
|
| Adult | 5 | 2021 | 214055 | 0.010 |
Why?
|
| Prognosis | 1 | 2003 | 29063 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 806 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3508 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2009 | 3913 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 975 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 565 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2005 | 1182 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 2242 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2008 | 6365 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 2234 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 40561 | 0.010 |
Why?
|
| Risk Factors | 1 | 2003 | 72290 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 6622 | 0.010 |
Why?
|
| United States | 1 | 2003 | 69872 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 8642 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 56430 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 13408 | 0.010 |
Why?
|
| Boston | 1 | 2005 | 9313 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 85781 | 0.010 |
Why?
|
| Male | 2 | 2006 | 350118 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 16689 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 21746 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 13881 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2005 | 63114 | 0.000 |
Why?
|